Literature DB >> 27322701

Cost-effectiveness of Management Options for Small Renal Mass: A Systematic Review.

Ye Wang1, Yu-Wei Chen, Jeffrey J Leow, Alison C Levy, Steven L Chang, Francisco-Hammerschmidt Gelpi.   

Abstract

Costs of surgery for small renal masses (SRMs) are high. This study aimed to systematically review and evaluate the cost-effectiveness analyses of management options for SRMs. Six databases were searched from inception to August 2015. Inclusion criteria were full original research, full economic evaluation of management options for SRM, and written in English. Among 776 studies screened, 6 met the inclusion criteria. Ablation was cost-effective versus nephron-sparing surgery. Laparoscopic partial nephrectomy was cost-effective versus the open approach. Renal mass biopsy dominated immediate treatment in the United States, but not in Canada. According to the Consolidated Health Economic Evaluation Reporting Standards, all the studies had relatively good quality. Despite the observed evidence, future research is needed to fill in the knowledge gap. A few suggestions should be kept in mind such as conducting the cost-effectiveness analysis in a variety of countries.

Entities:  

Mesh:

Year:  2016        PMID: 27322701     DOI: 10.1097/COC.0000000000000307

Source DB:  PubMed          Journal:  Am J Clin Oncol        ISSN: 0277-3732            Impact factor:   2.339


  6 in total

Review 1.  Surgical and Minimally Invasive Therapies for the Management of the Small Renal Mass.

Authors:  John Withington; Joana B Neves; Ravi Barod
Journal:  Curr Urol Rep       Date:  2017-08       Impact factor: 3.092

Review 2.  Focal ablation therapy for renal cancer in the era of active surveillance and minimally invasive partial nephrectomy.

Authors:  Serge Ginzburg; Jeffrey J Tomaszewski; Alexander Kutikov
Journal:  Nat Rev Urol       Date:  2017-09-12       Impact factor: 14.432

Review 3.  Systematic Review of Contemporary Evidence for the Management of T1 Renal Cell Carcinoma: What IRs Need to Know for Kidney Cancer Tumor Boards.

Authors:  Julie Cronan; Sean Dariushnia; Zachary Bercu; Robert Mitchell Ermentrout; Bill Majdalany; Laura Findeiss; Janice Newsome; Nima Kokabi
Journal:  Semin Intervent Radiol       Date:  2019-08-19       Impact factor: 1.513

Review 4.  Research on the Economics of Cancer-Related Health Care: An Overview of the Review Literature.

Authors:  Amy J Davidoff; Kaitlin Akif; Michael T Halpern
Journal:  J Natl Cancer Inst Monogr       Date:  2022-07-05

5.  Comprehensive assessment of the morbidity of renal mass biopsy: A population-based assessment of biopsy-related complications.

Authors:  Alaina Garbens; Christopher J D Wallis; Zachary Klaassen; Refik Saskin; Lesley Plumptre; Ronald Kodama; Sender Herschorn; Robert K Nam
Journal:  Can Urol Assoc J       Date:  2021-02       Impact factor: 1.862

6.  Deep learning based prediction of prognosis in nonmetastatic clear cell renal cell carcinoma.

Authors:  Seok-Soo Byun; Tak Sung Heo; Jeong Myeong Choi; Yeong Seok Jeong; Yu Seop Kim; Won Ki Lee; Chulho Kim
Journal:  Sci Rep       Date:  2021-01-13       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.